#image_title
Canada’s vaccine advisory group said Friday it recommends building toward immunizing all infants from respiratory syncytial virus (RSV).
The common and highly contagious virus normally causes cold-like symptoms. But for more vulnerable populations such as infants and older adults, it can lead to more serious illness like pneumonia and bronchiolitis; a swelling of the small airway passages in the lungs.
RSV infects almost all children by the time they reach two years of age. It is also a leading cause of hospitalization in infants and young children.
In 2023, researchers reported nearly half of children hospitalized for RSV in Canada’s pediatric hospitals in recent years were under six months of age. They called for preventative options to ease the pressure on intensive care units caring for the sickest.
Here are some key considerations in rolling out the shots.
Pfizer Canada’s vaccine RSVpreF (sold as Abrysvo), aims to prevent lower respiratory tract diseases caused by RSV, and was approved by Health Canada in January.
Sanofi’s nirsevimab (sold as Beyfortus) is a monoclonal antibody to protect infants in their first RSV season — the fall and winter — as well as children who remain vulnerable to severe disease in the next season.
The National Advisory Committee on Immunization (NACI) says the top priority for nirsevimab include:
Depending on cost effectiveness, the group also recommends considering universal immunization with nirsevimab for any infant less than eight months of age entering or born during their first RSV season.
Nirsevimab contains proteins made in the laboratory to mimic the immune system’s ability to fight off RSV, while RSVpreF is meant to protect infants in their first RSV season through passive immunity. When given in pregnancy, antibodies to fight the virus transfer to the fetus through the placenta.
NACI recommends that RSVpreF be considered as an individual decision together with information from the person’s pregnancy care provider, in advance of, or during, the RSV season, to prevent severe RSV disease in their infant.
Provinces and territories need to decide on access, cost-effectiveness and affordability of rolling the products out to prioritized infants or all of them.
Another RSV vaccine for seniors, from manufacturer GSK, was approved last August.
Trump became the first former US president convicted of felony charges and was originally set…
A woman from China has been arrested at a Vermont lake bordering Quebec for trying…
An estrogen-lowering program will include: Increase your fiber intake. That happens two ways: 1. Eat…
Andre De Grasse and Damian Warner are set to defend their Olympic titles at this…
Last month, Facinelli shared on Garth’s podcast that the kids were a big part of…
More than 60% of Filipinos want a code of conduct to govern the actions of…
This website uses cookies.